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Carbon nanotubes (CNTs) have been introduced recently as a novel carrier system for both small and large therapeutic molecules.
CNTs can be functionalized (i.e., surface engineered) with certain functional groups in order to manipulate their physical or bio-
logical properties. In addition to the ability of CNTs to act as carriers for a wide range of therapeutic molecules, their large surface
area and possibility to manipulate their surfaces and physical dimensions have been exploited for use in the photothermal destruc-
tion of cancer cells. This paper paper will discuss the therapeutic applications of CNTs with a major focus on their applications for
the treatment of cancer.
1.Introduction
The major aim of developing nanocarrier drug delivery sys-
tems is to enhance the therapeutic eﬀect or reduce toxicity
of therapeutically active materials. This is conventionally
achieved using spherically shaped vesicle nanocarriers such
as liposomes. Alternatively, carbon nanotubes (CNTs) are es-
sentially cylindrical molecules made of carbon atoms. CNTs
are graphene sheets rolled into a seamless cylinder that can
be open ended or capped, having a high aspect ratio with
diameters as small as 1nm and a length of several microm-
eters. CNTs made from a single graphene sheet results in
a single-walled nanotubes (SWNT) while several graphene
sheets make up multiwalled carbon nanotubes (MWNTs)
[1, 2]( Figure 1). Ever since their discovery in 1991 by Iijima
[1], there has been intense interest in these allotropes of
carbon due to their unique physical and chemical properties
and potential applications in a wide range of ﬁelds, from
electronic devices and sensors to nanocomposite materials
of high strength and low weight. Pristine CNTs are not
soluble. It was only after the development of strategies
to functionalize these molecules with organic groups and
render them soluble that opened the way to bioapplications
of CNTs. Due to their high surface area, they are capable of
adsorbing or conjugating with a wide variety of therapeutic
molecules. Thus, CNTs can be surface engineered (i.e.,
functionalized) in order to enhance their dispersability in
the aqueous phase or to provide the appropriate functional
groups that can bind to the desired therapeutic material or
the target tissue to elicit a therapeutic eﬀect. CNTs might
help the attached therapeutic molecule to penetrate through
the target cell to treat diseases [3–6] and a recent example
of CNTs with a variety of functional groups relevant to
cancer therapy [7] is shown in Figure 2.H e r e ,w ep r o v i d e
an overview of the therapeutic applications of CNTs with a
major focus on their use in the treatment of cancer.
2. Cellular Uptake of CNTs
ThecellularuptakeofCNTshasbeenconﬁrmedinarangeof
studies but the mechanism of CNT penetration into cells is
still not well understood. Because of their needle-like shapes,2 Journal of Drug Delivery
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Figure 1:Carbonnanotubes(CNTs)aregraphenesheetsrolledinto
a cylindrical shape. Several sheets may roll into MWNTs whilst a
single sheet rolls into a SWNT [2].
CNTs might be able to perforate cellular membrane and pass
into the cellular components without causing apparent cell
damage [3, 4, 8–11]. An in vitro CNTs nanoinjector system
has been developed by Chen and coworkers [6]. The nanoin-
jectorwasdesignedusinganatomicforcemicroscope(AFM)
tip and functionalized MWNTs attached to a model cargo
compound via a disulﬁde linker. The MWNTs nanoinjector
successfully transported into the cell where the disulﬁde
bond was broken, resulting in the release of the cargo com-
pound within the cytosol (Figure 3).
The perpendicular positioning of the nanotubes to the
cell membranes suggests that uptake of CNTs was similar to
that of nanoneedles which diﬀuse through cell membrane
without causing cell death [5]( Figure 4). In a study con-
ducted by Kam and coworkers [12], ﬂuoreceinated protein
attached to SWNTs-biotin was detected in the endosomes,
suggesting that uptake of the nanotubes occurred via endo-
cytosis. By contrast, no protein was internalized in the ab-
sence of the nanotubes. Using epiﬂuorescence and confocal
microscopy, functionalized CNTs labeled with a ﬂuorescent
agent have been shown to penetrate through the cell to the
cytoplasm or the nucleus of ﬁbroblasts [3]. In another study,
it has been reported that the uptake mechanism of MWNTs
is highly dependent on the length of nanotubes since those
which are shorter than 1μm were easier to internalize into
cells and the process of cellular uptake was reported not to
be via endocytosis [13].
3. CNTs as Carriersfor Drugs, Genes,
andProteins
CNTshavebeeninvestigatedaspotentialnanocarriersforthe
delivery of drugs, genes, and proteins. Most of the research
on CNTs has focused on their potential for delivery of
anticancer agents. This might be attributed to their unique
needle-like shapes which enable them to be functionalized in
order to adsorb or covalently link to a wide variety of ther-
apeutic materials and internalize them into the target cell.
Moreover,thewell-establishedsafetyofvesicle-basedcarriers
particularly liposomes has discouraged many researchers
from investigating CNTs in the treatment of many diseases
other than cancer.
3.1. CNTs as Carriers of Anticancer Molecules. It is well
known that cancer cells overexpress folic acid (FA) receptors,
and several research groups have designed nanocarriers with
engineered surfaces to which FA derivatives can be attached.
Moreover, nonspherical nanocarriers (e.g., CNTs) have been
reported to be retained in the lymph nodes for longer pe-
riods of time compared to spherical nanocarriers [14]( e . g . ,
liposomes). Thus, CNTs might be used for targeting lymph
node cancers as shown by various investigators [15–17]. In
these studies, magnetic nanoparticles containing the anti-
cancer cisplatin were entrapped into folic-acid-function-
alized MWNTs. An external magnet was employed to drag
the nanotubes to the lymph nodes where the drug was
shown to be released over several days and the tumor to
be selectively inhibited. In a recent study, Yang et al. [18]
have loaded the anticancer molecule gemcitabine into mag-
netic MWNTs and, using mice, they reported high activity
against lymph node metastasis when the formulation was
injected subcutaneously [18]. In another study, the poorly
water-soluble anticancer camptothecin has been loaded into
polyvinyl alcohol-functionalized MWNTs and reported to be
potentially eﬀective in treatment of breast and skin cancers
[19].
Dharandcoworkers[20]havedevelopedwhattheycalled
the “longboat delivery system” (Figure 5). A complex of cis-
platin and FA derivative was attached to a functionalized
SWNT via a number of amide bonds to comprise the
“longboat” which has been reported to be taken up by cancer
cells via endocytosis, followed by the release of the drug and
its subsequent interaction with the nuclear DNA. Another
platinum anticancer, namely, carboplatin, after being incor-
porated into CNTs has been shown to inhibit the prolif-
eration of urinary bladder cancer cells in vitro. In another
study, anticancer eﬀects have been shown to be dependent
on the method used to entrap the drug in the CNTs, which
highlighted the possible eﬀects of preparation conditions on
the therapeutic activity of therapeutic molecules associated
with CNTs [21].
Paclitaxel is a poorly water-soluble anticancer molecule.
In the commercialized paclitaxel product (Taxol), Cremo-
phor EL is used to solubilise the drug. Unfortunately, Cre-
mophor EL itself is toxic, which makes ﬁnding a suitable
alternative a high priority. Moreover, the circulation time of
Taxolisveryshort.Coatingthenanocarriers(e.g.,liposomes)
with hydrophilic polymers such as polyethylene glycol (PEG)
hasbeenestablishedasastrategytoprolongcirculationofthe
nanocarrier-entrappedmoleculesinthebloodbymakingthe
carrier highly evasive to uptake by the blood macrophages
[22, 23]. PEGylation of paclitaxel increases the circulation
time in the blood over Taxol [24]. Functionalized SWNTs
were conjugated with paclitaxel through branched PEG
chains via a cleavable ester bond. The resultant formulation
was more eﬀective in suppressing tumour growth in vivo
thanTaxolorpaclitaxel-PEGconjugateina4T1breastcancer
animal model. The PEGylated nanotubes were able to pro-
long the circulation and greatly enhance cellular uptake of
the drug by the cancer cells [25]. Similar ﬁndings of anti-
cancer activity have been recently shown when paclitaxel was
loaded into PEGylated SWNTs or MWNTs using HeLa cellsJournal of Drug Delivery 3
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Figure 2: (a) Schematic representation of functionalization of SWNTs with quantum dots, EDC, and cisplatin; (b) SWNT bioconjugated
withcisplatinandEGF,targetingcancercellsurfacereceptorEGFR;(c)–(e)TEMimagesshowingthevariousfunctionalgroups,withcisplat-
in shown as bright spots [7].
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Figure 3: A schematic diagram showing that an AFM-controlled
MWNT-based nanoinjector was able to penetrate into a cell and
releasetheattachedcargocompoundafterthebreakageofthedisul-
ﬁde bond. This was followed by successful retraction of the nanoin-
jector with no apparent cell damage being produced [6].
and MCF-7 cancer cell lines [26]. Multidrug resistance is
a signiﬁcant obstacle to successful anticancer drug therapy
since the P-glycoprotein eﬄux transporter can interfere with
the accumulation of anticancer drugs in the target cells, re-
sulting in reduced eﬀectiveness of therapy [27, 28]. Recently,
using hepatoma cell lines, PEGylated MWNTs have been
100nm
Figure 4: The perpendicular positioning of MWNTs (pointed at
by the white arrows) during internalization into HeLa cells suggests
that cellular uptake of CNTs by the cells was similar to that of
nanoneedles [5].4 Journal of Drug Delivery
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Figure 5: The “longboat” anticancer system in which the chemotherapeutic agent cisplatin is attached from one end to the FA derivative and
from the opposite end to a SWNT via an amide link [20].
shown to accumulate in multidrug resistant cells as eﬃcient
as in nonresistant cells, as observed by confocal microscopy
[29]. Interestingly, Liu and coworkers reported that although
PEGylation of SWNTs can prolong blood circulation time of
the associated anticancer molecule, it may cause an accumu-
lation of the nanotubes in the dermal tissues of mice, sug-
gesting that the degree of coating with PEG requires optimi-
sation [30].
Similar to FA receptors, biotin receptors may be over-
expressed on the surfaces of certain cancer cells. Therefore,
biotin-functionalizedSWNTsconjugatedwiththeanticancer
agenttaxoidusingacleavablelinkerhavebeendesigned[31].
The drug was transported via endocytosis, released in the
cell and interacted with microtubules as evaluated by ﬂow
cytometry. This resulted in the formation of a stable micro-
tubule-taxoid complex and ﬁnally caused apoptosis and cell
death (Figure 6).
A targeted delivery system of FA-tethered SWNTs-doxo-
rubicin (DOX) has been designed. Bioadhesive polymers
such as chitosan (CHI) and sodium alginate (ALG) were
included to enhance the aqueous dispersability of the nan-
otubes while FA was used to improve the targeting prop-
erties of the nanotubes (Figure 7). Transmission electron
microscopy (TEM) indicated that the drug was released after
being transported into the tumor cell (HeLa cell) at the low
pH of the lysosome [32] but not at the normal physiological
pH of 7.4 (Figure 8). Recently, a novel approach has been
introduced by covalently attaching PAMAM dendrimers to
FA-treated MWNTs. Using this approach to deliver nan-
otubes, ﬂow cytometry and confocal microscopy indicated
possible targeting of cancer cells that overexpress FA recep-
tors [33]. Li and coworkers (2011) have designed a novel
systemwhichwasreferredtoas“dual-targeteddrugnanocar-
rier” by conjugating MWNTs with iron nanoparticles and
folate molecules. This system was eﬃciently loaded with
doxorubicin and demonstrated superior delivery to HeLa
cells when compared to free doxorubicin [34].
3.2. CNTs as Carriers of Immunoactive Compounds, Proteins,
and Genetic Materials. The ability of macromolecules (e.g.,
genes) to cross the biological barriers and be expressed
within a target cell is particularly challenging, owing to their
hydrophilicity and large molecular size. Gene therapy aims
to use genetic material to treat diseased cells by repairing
the cause of the disease. Since genetic materials are poorly
able to cross the biological membranes, the use of viral or
nonviral vectors to carry the gene and internalize it into the
cell is necessary. Nonviral vectors are less eﬃcient than viral
vectors [35] and short lived [36]; however, they are far safer
[37, 38]. Pantarotto and coworkers have developed novel
functionalized SWNT-DNA complexes and reported high
DNA expression compared with naked DNA [4]. Generally,
functionalized SWNTs have been suggested as suitable non-
viral carriers of macromolecules and internalization of such
macromolecules into living cells by CNTs has been reported
to take place via energy-dependent endocytosis [39]. Confo-
calmicroscopyandﬂowcytometryhaveshownmuchgreater
ﬂuorescent activity of protein and DNA when conjugated to
SWNTsascomparedtothenakedmacromolecules[40]indi-
cating that CNTs are promising vectors for gene and protein.
Cai and coworkers have introduced an approach to gene
delivery named “carbon nanotube spearing” [10]. Plasmid
DNA with a ﬂuorescent protein were immobilized onto
nickel-embedded CNTs. The formulation was “speared” into
Bal 17 B lymphoma cells using a magnetic ﬁeld, which pro-
duced high transfection in the target cells [10]. In another
study, exposure of HeLa cells to DNA attached to SWNTs at
37◦Cresultedingeneinternalization.However,atlowertem-
perature (e.g., 4◦C), no internalization took place (Figure 9),
possibly because gene transport occurs by energy-dependent
endocytosis [39].
Am o r er e c e n ts t r a t e g yi ng e n et h e r a p y ,n a m e l y ,
gene silencing, involves the use of small interfering RNA
(siRNA).Thisapproachhasbeenshowneﬃcientinthetreat-
ment of many diseases including various cancers. In cancer,Journal of Drug Delivery 5
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antitumor immunity might be inhibited by suppressors of
cytokine signaling 1 (SOCS1). siRNA can be conjugated to
phospholipid-functionalized SWNTs using a cleavable disul-
ﬁde linker, resulting in eﬃcient gene silencing and subse-
quent death of the targeted cell [9] .I nar e c e n ts t u d y ,a m i n o -
functionalized MWNTs-siRNA complexes have shown suc-
cessful suppression of tumor and prolonged survival in lung
tumor of an animal model [41]. Many types of cancer (e.g.,
leukemia) can overexpress cyclinA(2), and suppression of
this material is expected to prevent tumor growth. Func-
tionalized SWNTs have been designed as carrier for siRNA
for internalization into K562 cells and subsequent inhibition
of the production of cyclinA(2) and treatment of chronic
myelogenous leukemia. It has been found that suppression
of cyclinA(2) expression using siRNA-CNTs can promote
apoptosis in the targeted tumor [42]. Similar ﬁndings have
been reported, for instance, functionalized SWNTs have
been conjugated to telomerase reverse transcriptase (TERT)
siRNA. The target gene was successfully silenced, and tumor
growth was inhibited in vitro using murine tumor cell lines
and in vivo using a mouse model [43]. In another study,
CNTs cationically functionalized with polyethylene imines
havebeenshowncapableofcomplexingwithsiRNAandgen-
erating a silencing activity of up to 30% and cytotoxicity of
up to 60% [44].
Streptavidin is a protein that has anticancer activity [45];
however, due to its very large molecular weight (approxi-
mately 60,000Da), it does not penetrate through cells. Kam
and coworkers [12] have used a conjugate of streptavidin
with SWNTs-biotin, which resulted in internalization of the
protein into model cancer cells by adsorption-mediated en-
docytosis. Transmission electron and confocal microscopy
have shown that MWNTs can act as transporters of the
recombinant ricin A chain protein, resulting in high death
ratesofcancercells(e.g.,upto75%ofHeLacellswerekilled)
[46].
Immunotherapy may be an alternative to gene therapy
in the treatment of cancer. Antitumor immunotherapy using
CNTs has been recently researched. Tumor-speciﬁc mono-
clonal antibodies, radiometal ion chelates, and ﬂuorescent
probe have been attached to SWNTs. Targeting the tumor
(lymphoma) using a range of techniques has been reported
to be successful [47]. MWNTs have been conjugated to
tumour lysate protein as an antigen. This speciﬁcally in-
creased the antitumor immune response [48].6 Journal of Drug Delivery
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Glioma is a brain tumor that is able to evade the host
immune system, resulting in lack of beneﬁt from conven-
tional chemotherapy. This is because glioma cells secrete
the immunosuppressive cytokines such as prostaglandins
E and TGF-Beta and IL-10 [17, 49]. Macrophages have a
preferential aﬃnity towards CNTs when compared to glioma
cells [50]. Using a GL261 murine intracranial glioma cancer
model, VanHandel and coworkers [51] have developed an
immunotherapy approach using MWNTs based on the fact
that macrophages prefer to engulf CNTs compared with
glioma cells. MWNTs caused an increase in the inﬂux of
macrophages into the glioma cells. This was reported to be
accompanied by an increase in the levels of IL-10 expression,
suggesting that immunomodulation using CNTs is a possible
strategy to treat cancer.
Angiogenesis targeting antibodies E4G10 were attached
to SWNTs via radiometal ion chelates. This formulation
has been reported to reduce the volume of the tumor and
prolong survival in animal models [52]. Moreover, oxidized
MWNTs can be injected subcutaneously to a hepatocarci-
noma-bearing animal to induce an immune response, which
has been reported to retard tumor growth [53]. This suggests
that CNTs themselves could possibly be surface-engineered
to have anticancer activity by inducing an immune response
against tumor.
A major obstacle to eﬀective anticancer therapy is the
multidrug resistance caused by enhanced eﬄux of anticancer
drugs by the overexpressed p-glycoprotein, resulting in poor
anticancer eﬀect. Li and coworkers (2010) have shown that
SWNTscanbefunctionalizedwithp-glycoproteinantibodies
and loaded with the anticancer agent doxorubicin. Com-
pared with free doxorubicin, this formulation demonstrated
higher cytotoxicity by 2.4-fold against K562R leukemia cells
[54].
3.3. Photothermal Therapy of Cancer Using CNTs. CNTs are
able to absorb light in the near infrared (NIR) region, result-
inginheatingofthenanotubes[55].Thisuniqueproperty of
CNTs has been exploited as a method to kill cancer cells via
thermal eﬀects [39, 56–68].
Optical coupling of light with CNTs is predicted to be
at highest when the length of the nanotubes is more than
half the wave length of the incident light beam as determined
by the antenna theory [66]. Engineering the structure of
MWNTs by creating intentional surface defects might en-
hance the antenna properties of the nanotubes. Such engi-
neered “defects” or dopants will cause scattering in the trav-
elling currents and also increase the heating of the nan-
otube.Thisphysicoelectroniccharacteristicoftheengineered
MWNTs can be employed to thermally destruct the tumor
cells by using MWNTs that have good heat conducting prop-
erties. Examples of dopants include boron [67] and nitrogen
[57](N-doping).N-dopedMWNTshavebeenshowntopro-
duce photoablative kill of model kidney cancer cells when
NIR light was used. Moreover, the length of nanotubes has
been found to be a major determinant of nanotube ability to
transfer heat and kill the tumor with lengths between 700
and 1,100 nm being most desirable to kill the tumor [57]
(Figure 10).
In a study conducted by Gannon and coworkers [56],
SWNTs were functionalized using Kentera (a polyphenylene
ethynylene-based polymer). The incubation of the nano-
tubes with hepatic tumor cells followed by application of
radiofrequencyﬁeldcausedaconcentration-dependentther-
mal destruction of the tumor cells which was demonstrated
by development of apoptotic cells that caused complete ne-
crosis of the tumor cells. By contrast, tumor cells that were
injected with the Kentera alone (without CNTs) were viable
after the application of the radiofrequency ﬁeld. In the same
study, it has been reported that in vivo injection of the
Kentera-functionalizedSWNTs wastoleratedby rabbits[56].
Unfortunately, the resultant thermal destruction is not
selective towards cancer cells and the access to deep tumor
areas is generally poor, necessitating the inclusion of tar-
geting moieties such as FA on the surfaces of CNTs [37].
Folate-bearing nanotubes having the size of 0.81nm and a
maximumabsorbanceat980nmwereusedforphotothermal
therapy of cancer [58] .T h et u m o rc e l l sw e r ee x p o s e dt o
980nm laser radiations, resulting in photothermal destruc-
tion of cancer cells both in vitro and in vivo.Journal of Drug Delivery 7
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Figure 8: TEM showing the diﬀerence between HeLa cancer cells before treatment and after treatment with carbon nanotube formulations
andthefateofthenanotubes:(a)HeLacellsbeforetreatment,(b)HeLacellstreatedwithDOX-FA-CHI-ALG-SWNTs,(c)amagniﬁedimage
of (b), and (d) magniﬁed image of the boxed region in (c). The black arrow points at a SWNT-containing vesicle, and the white arrow points
at some aggregated nanotubes inside a lysosome [32].
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Figure 9: Confocal microscopy showing the internalization of labeled single strand DNA into Hela cell using SWNTs. (a) The labeled DNA
(green colour) is surrounding the nucleus (black circles) at 37◦C. (b) The nucleus stained using DRAQ5 (red color) is surrounded by the
labeled DNA (green colour) after internalization at 37◦C. (c) At 4◦C, no DNA internalization has occurred [39].
3.4. CNTs for Other Therapeutic Applications. The use of
CNTshasbeenexpandingtoincludetherapeuticapplications
other than cancer. For instance, surface-engineered CNTs
may be able to capture pathogenic bacteria in liquid medium
[69–71]. Thus, CNTs themselves might have antimicrobial
activity since microorganisms may be adsorbed onto the
engineered surfaces of CNTs. Moreover, using E. coli as a
model microorganism, it has been reported that the elec-
tronic properties of SWNTs may regulate their antibacterial
activity. The antibacterial eﬀect was attributed to carbon-
nanotube-induced oxidation of the intracellular antioxidant
glutathione, resulting in increased oxidative stress on the
bacterial cells and eventual death [72].
Functionalized CNTs have been demonstrated to be able
t oa cta sc a rri e r sf o ra n t i m i c r o b i a la g e n t ss u c ha st h ea n t i f u n -
gal amphotericin B [73, 74]. CNTs can attach covalently to
amphotericin B and transport it into mammalian cells. This
reduced the antifungal toxicity as compared to the toxicity of
the free drug since 40% of the cells were killed by the CNTs-
free formulation compared to no cell death by the CNTs for-
mulation. It has also been reported that the antifungal activ-
ity was increased using the CNTs [73].
4. Conclusions
CNTs are promising needle-like carriers of both small drug
molecules as well as macromolecules such as genes and pro-
teins. CNTs can be functionalized so that certain molecules
are attached to their surfaces via covalent or noncovalent
bonding. The needle-like shape of the CNTs enables them to
perforate cellular membranes and transport the carried ther-
apeutic molecules to the cellular components. This process8 Journal of Drug Delivery
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Figure 10: The relationship between cell survival and CNTs length
using photothermal therapy. This has shown that nanotube lengths
of 700 and 1100nm are much more desirable in killing tumor cells
compared with the length of 300nm [57].
is thought to take place via endocytosis. CNTs have exclusive
properties that would make them appropriate in the medical
ﬁeld such as their ability to adsorb pathogenic microorgan-
isms and conduct heat. CNTs have been introduced to drug
delivery research for a limited number of years and therefore
extensive amounts of research is expected to be produced
in the forthcoming years in order to explore their poten-
tial.
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